EFFICACY AND SAFETY OF TRICHURIS SUIS OVA FOR TREATMENT OF MILDLY-TO-MODERATELY ACTIVE CROHN’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY

(1) Klinikum Der Johann Wolfgang Goethe-Universität Frankfurt A.m, Frankfurt A.m., Germany

(2) Abt. Gastroenterologie, Uk-Sh Campus Lübeck, Lübeck, Germany

(3) Abt. Gastroenterologie, Spital Netz Bern Tiefenau, Bern, Switzerland

(4) Div. Of Gastroenterology And Hepatology, University Of Zurich, Zurich, Switzerland

(5) Integrative Gastroenterologie, Internal And Integrative Medicine, Kliniken Essen-Mitte, Essen, Germany

(6) Hamburgisches Forschungsinstitut Für Ced, Hafced Gmbh&co.kg, Hamburg, Germany

(7) Universitätsklinik Für Innere Medizin Iii, Medizinische Universität Wien, Vienna, Austria

(8) Dept. Of Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark

(9) Medizinische Hochschule Hannover, Hannover, Germany

(10) Abt. Gastroenterologie, Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany

(11) Ärztehaus Am Klinikum, Schwalmstadt, Germany

(12) Gastroenterologische Gemeinschaftspraxis, Leipzig, Germany

(13) Abt. Innere Medizin I, Robert-Bosch-Krankenhaus, Stuttgart, Germany

(14) Klinik Für Innere Medizin I, Universitätsklinikum Ulm, Ulm, Germany

(15) Dept. Of Internal Medicine I, University Hospital Of Regensburg, Regensburg, Germany

(16) Dr. Falk Pharma Gmbh, Freiburg, Germany



This item was part of the Targeting new pathways in IBD session at UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)

Categorisation:

  • Format
    • Abstract
  • Year
    • 2014